Rapamycin

Rapamycin (sirolimus) was discovered in a soil bacterium from Easter Island in the 1970s and entered medicine as an immunosuppressant for organ transplantation. Its longevity credentials emerged dramatically in 2009 when the Interventions Testing Program at the National Institute on Aging demonstrated that rapamycin extended lifespan in mice by 9–14% even when begun late in life — the equivalent of starting an intervention in 60-year-old humans. Since then, lifespan extension by rapamycin has been replicated across yeast, worms, flies, and mice, making it the most consistently validated pharmacological longevity intervention in biology. The mechanism centers on mTOR (mechanistic target of rapamycin), a master nutrient-sensing kinase that acts as a cellular growth-or-maintain switch. When nutrients are abundant, mTOR promotes protein synthesis, cell growth, and proliferation. When mTOR is inhibited — by caloric restriction, fasting, or rapamycin — cells shift into maintenance mode: autophagy is upregulated, protein quality control improves, and stem cell quiescence is better preserved. This broadly maps to at least four aging hallmarks: deregulated nutrient sensing, disabled macroautophagy, loss of proteostasis, and stem cell exhaustion. For healthy human longevity applications, the key question has been whether intermittent low-dose protocols could capture the benefits without the immunosuppressive side effects seen at transplant doses. The PEARL trial (PMC12074816) addressed this directly: 48 weeks of intermittent low-dose rapamycin in healthy older adults was safe, well-tolerated, and notably improved lean tissue mass in women. Blood panels, immune function, and infection rates showed no significant adverse deviations. Typical biohacker dosing is 5–10mg once weekly, often prescribed off-label by longevity physicians. Side effects at these doses include occasional mouth sores (aphthous ulcers), mild lipid changes, and transient glucose perturbations. The pharmacodynamic rationale for weekly dosing: full mTOR inhibition during the 24–48 hours post-dose, with recovery of mTORC2 (responsible for insulin signaling and immune function) between doses. This intermittent approach is specifically designed to capture autophagy and proteostasis benefits while minimizing immunosuppression.